Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOUNTAINEER: Tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer
2020-000540-60Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucatinib and trastuzumab in colorectal adenocarcinoma (mCRC), metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (2 cohorts), sponsored by Seagen Inc. Primary endpoint: Confirmed objective response rate (cORR) per RECIST 1.1 by BICR in pooled Cohorts A+B. Started May 2020; status: completed.
02
Drugs
tucatinibtrastuzumab
03
Conditions
colorectal adenocarcinoma (mCRC)metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-000540-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000540-60.